风湿性心脏病二尖瓣病变患者瓣膜替换术后肺功能的改变

目的：了解风湿性心脏病二尖瓣病变患者二尖瓣替换术（ＭＶＲ）后肺功能的改变。方法：观察２６例风湿性心脏病二尖瓣病变患者ＭＶＲ术前和术后３～１２个月的肺功能改变。结果：ＭＶＲ后３个月的肺功能与术前相比，无明显好转。术后６～１２个月，患者的各通气功能指标均有明显增加（Ｐ＜０．０５～Ｐ＜０．０１），但肺的一氧化碳弥散功能（ＤＬＣＯ）术后不但无增加，反而有下降的趋势。结论：ＭＶＲ术后３个月患者的肺功能与术前相比，无明显好转，可能与剖胸手术创伤有关。随着心功能的改善，术后６～１２个月，患者的通气功能逐渐改善，但ＤＬＣＯ并不增加，推测可能与患者术后肺泡毛细血管容量减少以及肺组织结构损害不可逆性改变有关。     

二尖瓣成形术与二尖瓣置换术治疗退行性二尖瓣关闭不全的远期疗效比较研究

背景退行性变是西方国家二尖瓣关闭不全常见的病因,与二尖瓣置换术(MVR)相比,二尖瓣成形术(MVP)不仅无需长期抗凝,避免了抗凝相关并发症,而且能够有助于左心功能的维护。目前MVR与MVP治疗退行性变的远期疗效尚不明确。目的比较MVP与MVR治疗退行性二尖瓣关闭不全的远期疗效。方法选取2003—2008年在俄罗斯巴库列夫心血管外科研究中心接受瓣膜手术的退行性二尖瓣关闭不全患者274例为研究对象。根据手术方式的不同,将患者分为MVP组(129例)和MVR组(145例)。收集患者一般资料,统计患者5年、10年累积生存率、无脑卒中发生率及再次瓣膜手术情况。分别根据患者随访终点时死亡情况、脑卒中发生情况,将患者分为死亡组(42例)和非死亡组(232例)、脑卒中组(30例)和非脑卒中组(244例)。采用单因素分析和多因素Cox回归分析探讨退行性二尖瓣关闭不全患者死亡、发生脑卒中的影响因素。结果MVP组患者体外循环时间、主动脉阻断时间、术后住院时间长于MVR组(P<0.05)。死亡组患者体外循环时间、呼吸机使用时间长于非死亡组,MVP率低于非死亡组(P<0.05)。脑卒中组患者入院时血肌酐、入院时左心室射血分数(LVEF)高于非脑卒中组,MVP率低于非脑卒中组(P<0.05)。多因素Cox回归分析结果显示,MVP是退行性二尖瓣关闭不全患者死亡[HR=0.053,95%CI(0.005,0.585)]、发生脑卒中[HR=0.095,95%CI(0.013,0.698)]的保护因素(P<0.05)。MVP组患者5年累积生存率低于MVR组,10年累积生存率高于MVR组(P<0.05)。MVP组患者5年、10年累积无脑卒中发生率低于MVR组(P<0.05)。MVP组和MVR组患者再次瓣膜手术率比较,差异无统计学意义(P>0.05)。结论MVP是退行性二尖瓣关闭不全患者死亡、发生脑卒中的保护因素,对于退行性二尖瓣关闭不全患者,行MVP者的远期预后优于行MVR者,临床应积极推广MVP。     

Short-Term Results of Transapical Transcatheter Mitral Valve Implantation for Mitral Regurgitation

Background

Mitral regurgitation (MR) is the most common valvular heart disease, and mitral valve surgery is the gold standard therapy for severe MR. Many patients with severe MR are not referred for surgery because of old age, comorbidities, or severe left ventricular dysfunction. Transcatheter mitral valve implantation may be a better therapeutic option for these high-risk patients with severe symptomatic MR.

Objectives

This study sought to describe the first-in-man series of transapical mitral valve implantation for mitral regurgitation with the TIARA device.

Methods

Extensive preclinical ex vivo and animal studies were conducted with the transapical mitral valve implantation of the Tiara system. The first 2 cases of human implantation were successfully performed in a 73-year-old man and a 61-year-old woman with severe functional MR. Both patients were in New York Heart Association class IV heart failure with depressed left ventricular ejection fraction, pulmonary hypertension, and additional comorbidities.

Results

The valve was implanted uneventfully in both patients. General anesthesia and transapical access were used. Patients were hemodynamically stable with no need for cardiopulmonary bypass. Immediately after implantation, systemic arterial pressure and stroke volume increased and pulmonary pressure decreased dramatically. There were no intraoperative complications, and both patients were extubated in the operating room. Post-procedural echocardiograms at 48 h, 1 month, and 2 months demonstrated excellent prosthetic valve function with a low transvalvular gradient and no left ventricular outflow tract obstruction. There was a trivial paravalvular leak in the first patient at 48 h, which was completely resolved at subsequent studies; no paravalvular leak occurred in the second patient.

Conclusions

Transapical transcatheter mitral valve implantation is technically feasible and can be performed safely. Early hemodynamic performance of the prosthesis was excellent. Transcatheter mitral valve implantation may become an important treatment option for patients with severe MR who are at high operative risk.     

Mitral leaflet separation index. An easy two dimensional echocardiography technique for assessment of mitral valve area before and after percutaneous balloon mitral valvuloplasty

Aim

To evaluate the reliability of the mitral leaflet separation (MLS) index against the traditional echocardiographic methods in measuring mitral valve area (MVA) pre and post percutaneous balloon mitral valvuloplasty (PBMV).

State of the Art: Degenerative Mitral Valve Disease

Mitral valve repair is the treatment of choice for severe mitral regurgitation. It offers superior long-term survival, freedom from cardiac events and quality of life to mitral valve replacement, and medical management. As a result increasing numbers of minimally symptomatic patients with preserved left ventricular function are being referred for mitral valve repair: long term outcomes in these patients have been shown to be similar to that of the general population. A clear understanding of the aetiology, lesions and valve dysfunction is necessary to guide timing and choice of treatment.     

Long-term Outcomes of Mitral Valve Repair Versus Replacement for Degenerative Disease: A Systematic Review

The short-term advantage of mitral valve repair versus replacement for degenerative disease has been extensively documented. These advantages include lower operative mortality, improved survival, better preservation of left-ventricular function, shorter post-operative hospital stay, lower total costs, and fewer valve-related complications, including thromboembolism, anticoagulation-related bleeding events and late prosthetic dysfunction. More recent written data are available indicating the long-term advantage of repair versus replacement. While at some institutions, the repair rate for degenerative disease may exceed 90%, the national average in 2007 was only 69%. Making direct comparisons between mitral valve repair and replacement using the available studies does present some challenges however, as there are often differences in baseline characteristics between patient groups as well as other dissimilarities between studies. The purpose of this review is to systematically summarize the long-term survival and reoperation data of mitral valve repair versus replacement for degenerative disease. A PubMed search was done and resulted in 12 studies that met our study criteria for comparing mitral valve repair versus replacement for degenerative disease. A systematic review was then conducted abstracting survival and reoperation data.     

Risk Factors for Midterm Cardiac Function Deterioration After Valve Replacement Surgery in Patients With Rheumatic Mitral Stenosis

BackgroundA symptomatic reduction in left ventricular ejection fraction (LVEF) is the main reason for postoperative heart failure after valve replacement surgery. However, postoperative heart failure occurs in patients with normal preoperative LVEF. Therefore, we examined clinical and echocardiographic data of patients with rheumatic heart disease to determine additional risk factors for low LVEF in the postoperative period.Methods and ResultsNinety-seven patients with rheumatic heart disease (RHD) who underwent mitral valve replacement for severe mitral valve stenosis were included retrospectively in this study. All patients had normal LVEF before surgery. Patients were divided into 2 groups based on postoperative LVEF 6 months after surgery. Groups A had normal postoperative LVEF (82 cases, 84.5%), and group B had low postoperative LVEF (15 cases, 15.5%). Clinical and electrocardiographic data were collected to determine risk factors for deterioration in cardiac function.Multivariate analysis revealed that preoperative low systolic peak velocities at the lateral tricuspid annulus (St) and no or mild aortic stenosis were independent risk factors for cardiac deterioration in patients with normal preoperative LVEF. Individuals with preoperative St ≤4.8 cm/s were more likely to develop lower LVEF at follow-up (χ² = 7.54; P = .006; odds ratio 5.03, 95% confidence interval 1.31–20.82). All 15 patients who had normal preoperative LVEF but abnormal postoperative LVEF had no or only mild aortic valve stenosis.ConclusionsDecreased right ventricular function and no or mild aortic stenosis were independent risk factors for low LVEF at follow-up in patients with RHD who had normal preoperative LVEF. The velocity of the tricuspid valve ring should be included in preoperative evaluations to improve the accuracy of postsurgical prognosis and clinical decision making.